.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,846,765

« Back to Dashboard

Details for Patent: 5,846,765

Title: Identification of novel substrates
Abstract:A method for identifying and selecting novel substrates for enzymes is provided. The method comprises constructing a gene fusion comprising DNA encoding a polypeptide fused to DNA encoding a substrate peptide, which in turn is fused to DNA encoding at least a portion of a phage coat protein. The DNA encoding the substrate peptide is mutated at one or more codons thereby generating a family of mutants. The fusion protein is expressed on the surface of a phagemid particle and subjected to chemical or enzymatic modification of the substrate peptide. Those phagemid particles which have been modified are then separated from those that have not.
Inventor(s): Matthews; David J. (San Francisco, CA), Wells; James A. (Burlingame, CA), Zoller; Mark J. (San Francisco, CA)
Assignee: Genentech, Inc. (South San Francisco, CA)
Filing Date:May 16, 1995
Application Number:08/441,871
Claims:1. A method for selecting novel polypeptide substrates comprising:

(a) constructing a replicable expression vector comprising a transcription regulatory element operably linked to a gene fusion, wherein the gene fusion comprises:

(i) a first gene encoding a polypeptide;

(ii) a second gene encoding a substrate peptide; and

(iii) a third gene encoding at least a portion of a phage coat protein,

wherein the 3' end of the first gene is linked to the 5' end of the second gene, and the 3' end of the second gene is linked to the 5' end of the third gene;

(b) mutating the vector at one or more selected positions within the second gene thereby forming a family of related plasmids encoding substrate peptides;

(c) transforming suitable host cells with the plasmids;

(d) infecting the transformed host cells with a helper phage having a gene encoding the phage coat protein;

(e) culturing the transformed infected host cells under conditions suitable for forming recombinant phagemid particles containing at least a portion of the plasmid and capable of transforming the host, the conditions adjusted so that no more than a minor amount of phagemid particles display more than one copy of the fusion protein on the surface of the particle;

(f) exposing the phagemid particles to a process capable of modifying at least one covalent bond of an amino acid in the substrate peptide of at least a portion of the phagemid particles;

(g) contacting the family of exposed phagemid particles with an affinity molecule, wherein the affinity molecule has affinity for the amino acid residue having the modified covalent bond; and

(h) separating the phagemid particles that bind to the affinity molecule from those that do not.

2. The method of claim 1 wherein the process comprises a post-translational covalent bond modifying process selected from the group consisting of a phosphorylation, glycosylation, carboxylation, ADP-ribosylation, methylation, isoprenylation and acylation.

3. The method of claim 2 wherein the process comprises phosphorylation of an amino acid selected from Thr, Ser, and Tyr.

4. The method of claim 2 wherein the affinity molecule is a monoclonal antibody having specificity for the modified amino acid of the process.

5. The method of claim 2 wherein the phagemid particles that bind the affinity molecule are eluted, infected into suitable host cells, and steps (d) through (h) are repeated two or more times.

6. The method of claim 2 wherein the phagemid particles that do not bind to the affinity molecule are infected into suitable host cells and steps (d) through (h) are repeated two or more times.

7. A method for selecting novel polypeptides substrates comprising:

(a) constructing a replicable expression vector comprising a transcription regulatory element operably linked to a gene fusion, wherein the gene fusion comprises:

(i) a first gene encoding a polypeptide;

(ii) a second gene encoding a substrate peptide; and

(iii) a third gene encoding at least a portion of a phage coat protein,

wherein the 3' end of the first gene is linked to the 5' end of the second gene, and the 3' end of the second gene is linked to the 5' end of the third gene;

(b) mutating the vector at one or more selected positions within the second gene thereby forming a family of related plasmids encoding substrate peptides;

(c) transforming suitable host cells with the plasmids;

(d) infecting the transformed host cells with a helper phage having a gene encoding the phage coat protein;

(e) culturing the transformed infected host cells under conditions suitable for forming recombinant phagemid particles containing at least a portion of the plasmid and capable of transforming the host, the conditions adjusted so that no more than a minor amount of phagemid particles display more than one copy of the fusion protein on the surface of the particle;

(f) exposing the phagemid particles to a process capable of modifying at least one covalent bond of an amino acid residue in the substrate peptide of at least a portion of the phagemid particles;

(g) derivatizing the modified amino acid residue with a substituent capable of binding with an affinity molecule;

(h) contacting the family of exposed derivitized particles with an affinity molecule, wherein the affinity molecule has affinity for the substituent; and

(i) separating the phagemid particle that bind to the affinity molecule from those that do not.

8. The method of claim 7 wherein the process comprises a post-translational covalent bond modifying process selected from the group consisting of a phosphorylation, glycosylation, carboxylation, ADP-ribosylation, methylation, isoprenylation and acylation.

9. The method of claim 8 wherein the process comprises phosphorylation of an amino acid selected from Thr, Ser, and Tyr.

10. The method of claim 8 wherein the process comprises glycosylation of an amino acid selected from Asn, Ser, and Thr.

11. The method of claim 8 wherein the phagemid particles that bind the affinity molecule are eluted, infected into suitable host cells, and steps (d) through (h) are repeated two or more times.

12. The method of claim 8 wherein the phagemid particles that do not bind to the affinity molecule are infected into suitable host cells and steps (d) through (h) are repeated two or more times.

13. A method for selecting novel polypeptides substrates, comprising:

(a) constructing a family of replicable expression vectors comprising a transcription regulatory element operably linked to a gene fusion, wherein the gene fusion comprises a gene encoding a substrate peptide and a gene encoding at least a portion of a phage coat protein, wherein the 3' end of the gene encoding the substrate peptide is linked to the 5' end of the gene encoding at least a portion of the phage coat protein;

(b) transforming suitable host cells with the replicable expression vectors;

(c) infecting the transformed host cells with a helper phage having a gene encoding the phage coat protein;

(d) culturing the transformed infected host cells under conditions suitable for forming recombinant phagemid particles containing at least a portion of the replicable expression vector and capable of transforming the host cells, the conditions adjusted so that no more than a minor amount of phagemid particles display more than one copy of the fusion protein on the surface of the particles;

(e) exposing the phagemid particles to a process capable of modifying at least one covalent bond of an amino acid in the substrate peptide of at least a portion of the phagemid particles;

(f) contacting the family of exposed phagemid particles with an affinity molecule, wherein the affinity molecule has affinity for the amino acid residue having the modified covalent bond; and

(g) separating the phagemid particles that bind to the affinity molecule from those that do not bind.

14. A method for selecting novel polypeptides substrates, comprising:

(a) constructing a family of replicable expression vectors comprising a transcription regulatory element operably linked to a gene fusion, wherein the gene fusion comprises a gene encoding a substrate peptide and a gene encoding at least a portion of a phage coat protein, wherein the 3' end of the gene encoding the substrate peptide is linked to the 5' end of the gene encoding at least a portion of the phage coat protein;

(b) transforming suitable host cells with the replicable expression vectors;

(c) infecting the transformed host cells with a helper phage having a gene encoding the phage coat protein;

(d) culturing the transformed infected host cells under conditions suitable for forming recombinant phagemid particles containing at least a portion of the replicable expression vector and capable of transforming the host cells, these conditions adjusted so that no more than a minor amount of phagemid particles display more than one copy of the fusion protein on the surface of the particles;

(e) exposing the phagemid particles to a process capable of modifying at least one covalent bond of an amino acid residue in the substrate peptide of at least a portion of the phagemid particles;

(f) derivatizing the modified amino acid residue with a substituent capable of binding with an affinity molecule;

(g) contacting the derivatized particles with an affinity molecule, wherein the affinity molecule has affinity for the substituent; and

(h) separating the phagemid particles that bind to the affinity molecule from those that do not bind.

15. A method for selecting novel polypeptides, comprising:

(a) constructing a family of phagemid particles which display different polypeptides fused to at least a portion of a phage coat protein on the surface thereof, wherein no more than a minor amount of phagemid particles display more than one copy of the fusion protein on the surface of the particles;

(b) exposing the phagemid particles to a process capable of modifying at least one covalent bond of an amino acid in the polypeptide of at least a portion of the phagemid particles;

(c) contacting the family of exposed phagemid particles with an affinity molecule, wherein the affinity molecule has affinity for the amino acid residue having the modified covalent bond; and

(d) separating the phagemid particles that bind to the affinity molecule from those that do not bind.

16. A method of claim 15, further comprising

(e) infecting suitable host cells with the phagemid particles that bind or do not bind to the affinity molecule to produce a second family of phagemid particles and repeating steps (b)-(d).
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc